Skip to content

Regeneron Pharmaceuticals

US · REGN #285 by market cap Listed 1970
742.12 +3.40 +0.46%
Live - 5344 symbols - heartbeat 74s ago · 2026-10-08 05:13
Pre-market 742.00 -0.02%
After-hours 742.12 0.00%
Overnight 741.93 -0.03%
Market cap
76.40B
P/B
2.41
EPS
41.48
Reader sentiment Are you bullish or bearish on REGN?

Anonymous reader poll. Unscientific, not investment advice.

Recent news

  • Rating change
    A Quick Look at Today's Ratings for Regeneron Pharmaceuticals(REGN.US), With a Forecast Between $696 to $769
    Market Newswire · 2026/7/8
  • Rating change
    Goldman Sachs Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $965
    Market Newswire · 2026/7/22
  • Rating change
    Guggenheim Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $1,000
    Market Newswire · 2026/7/22
  • J.P. Morgan Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $900
    Market Newswire · 2026/8/5
  • Rating change
    Citi Maintains Regeneron Pharmaceuticals(REGN.US) With Hold Rating, Maintains Target Price $700
    Market Newswire · 2026/7/16
  • Rating change
    Wells Fargo Maintains Regeneron Pharmaceuticals(REGN.US) With Hold Rating, Maintains Target Price $700
    Market Newswire · 2026/7/9
  • Rating change
    Morgan Stanley Maintains Regeneron Pharmaceuticals(REGN.US) With Hold Rating, Cuts Target Price to $730
    Market Newswire · 2026/7/8
  • Analysts' Opinions Are Mixed on These Healthcare Stocks: Regeneron (REGN), Cytokinetics (CYTK) and Biohaven Ltd. (BHVN)
    TipRanks · 2026/9/10
  • Leerink Partners Downgrades Regeneron Pharmaceuticals(REGN.US) to Hold Rating, Announces Target Price $824
    Market Newswire · 2026/8/17
  • Rating change
    BofA Securities Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $856
    Market Newswire · 2026/7/13
  • Rating change
    Piper Sandler Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $854
    Market Newswire · 2026/7/9
  • Company notice
    LYC Healthcare: MEXTER TECHNOLOGY BERHAD (MEXTER) • PROPOSED ACQUISITION BY ITS 80% OWNED SUBSIDIARY MEXCOMM SDN BHD (777810-D) OF A 49% EQUITY INTEREST IN E-G6 SOLUTION (THAILAND) CO. LTD. (REGN NO. 0105551096920) (“THE COMPANY”) (“ACQUISITION”
    Bursa Malaysia · 2012/8/6
  • Rating change
    Guggenheim Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $1,030
    Market Newswire · 2026/8/3
  • Rating change
    BMO Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $730
    Market Newswire · 2026/7/13
  • HSBC Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $920
    Market Newswire · 2026/9/10
  • Rating change
    Barclays Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $917
    Market Newswire · 2026/8/5
  • Rating change
    CCORF Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $875
    Market Newswire · 2026/7/22
  • Rating change
    A Quick Look at Today's Ratings for Regeneron Pharmaceuticals(REGN.US), With a Forecast Between $750 to $960
    Market Newswire · 2026/7/31
  • J.P. Morgan Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $900
    Market Newswire · 2026/9/26

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-10-08 05:13:24 · For reference only, not investment advice and not tailored to your situation.